Iterum Therapeutics plc ITRMF

Full chart Compare

Set alert

0.00 USD 0.00 (+0.00%)

At closeNov 9, 2026, 4:00 PM EST

0.024 Day range 0.0249

0.00001 52-week range 0.6249

YTD: -100.00%
1 year: -100.00%

News

7 months ago reuters.com Iterum files wind-up petition due to limited cash, inability to raise equity Iterum Therapeutics said on Friday it has filed a petition in Ireland's High Court to wind up the drugmaker and was placed ‌into provisional liquidation, with a hearing set for April 13.
7 months ago globenewswire.com Iterum Therapeutics Announces Filing of Winding Up Petition DUBLIN and CHICAGO, March 27, 2026 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (in Provisional Liquidation) (Nasdaq: ITRM) (the “Company” or “Iterum” or “we”), a company focused on delivering next…
9 months ago globenewswire.com Iterum Therapeutics Provides Business Update --Expanded Market Access and Patent Protection for ORLYNVAH™ --FDA correspondence regarding the use of ORLYNVAH™ as step-down therapy DUBLIN and CHICAGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Iterum…
10 months ago globenewswire.com Iterum Therapeutics Provides Business Update DUBLIN and CHICAGO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum” or “we”), a company focused on delivering next generation oral and IV…
10 months ago globenewswire.com Iterum Therapeutics Provides Business Update DUBLIN and CHICAGO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum” or “we”), a company focused on delivering next generation oral and IV…
11 months ago globenewswire.com Iterum Therapeutics Provides Business Update DUBLIN and CHICAGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum” or “we”), a company focused on delivering next generation oral and IV…
11 months ago globenewswire.com Iterum Therapeutics Provides Business Update DUBLIN, Ireland and CHICAGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a company focused on delivering next generation oral and IV…
12 months ago seekingalpha.com Iterum Therapeutics plc (ITRM) Q3 2025 Earnings Call Transcript Iterum Therapeutics plc ( ITRM ) Q3 2025 Earnings Call November 14, 2025 8:30 AM EST Company Participants Kevin Dalton Corey Fishman - President, CEO & Director Christine Coyne - Chief Commercial…
12 months ago globenewswire.com Iterum Therapeutics Reports Third Quarter 2025 Financial Results - -Commercially Launched ORLYNVAH ™ in the United States in August 2025-- --Extended Cash Runway into Q2 2026-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, Nov.…
1 year ago globenewswire.com Iterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025 DUBLIN, Ireland and CHICAGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat…
1 year ago globenewswire.com Iterum Therapeutics to Present Data at IDWeek 2025 DUBLIN and CHICAGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections…
1 year ago globenewswire.com Iterum Therapeutics Provides Business Update DUBLIN and CHICAGO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a company focused on delivering next generation oral and IV antibiotics to treat infections…
1 year ago globenewswire.com Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S. FDA-approved antibiotic with the power of a penem in a novel oral formulation, offering a vital alternative in treating uncomplicated urinary tract infections FDA-approved antibiotic with the power…
1 year ago fool.com ITRM Reports Results ITRM Reports Results
1 year ago seekingalpha.com Iterum Therapeutics plc (ITRM) Q2 2025 Earnings Call Transcript Iterum Therapeutics plc (NASDAQ:ITRM ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Corey N. Fishman - President, CEO & Director Judith M.
1 year ago globenewswire.com Iterum Therapeutics Reports Second Quarter 2025 Financial Results - - Launch of ORLYNVAH TM Expected August 2025— - -Cash Runway into 2026-- --Company to host conference call today at 8:30amET-- DUBLIN and CHICAGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Iterum…
1 year ago globenewswire.com Iterum Therapeutics to Report Second Quarter 2025 Financial Results on August 5, 2025 DUBLIN, Ireland and CHICAGO, July 29, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat…
1 year ago globenewswire.com Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DUBLIN and CHICAGO, July 02, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum” or the “Company”), a company committed to delivering next generation oral and IV antibiotics to…
1 year ago globenewswire.com Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth DUBLIN and CHICAGO, June 30, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum” or the “Company”), a company committed to delivering next generation oral and IV antibiotics to…
1 year ago globenewswire.com Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence 9.2% of Patients in REASSURE's Primary Population had a Baseline Pathogen Resistant to Three or More Classes of Antibiotics 9.2% of Patients in REASSURE's Primary Population had a Baseline Pathogen…